Showing results (311-320 of 395) with videos related to
Sort By:
Pageof 40
Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.Nature Communications|January 25, 2025
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLLLavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C Byrd, Peter Hillmen, Paolo Ghia, et al.Hemasphere|May 1, 2026
Chronic lymphocytic leukemia with IGH::BCL3-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscapeCosima Drewes, Cristina López, Juan Emilio Martinez-Manjón, et al.Haematologica|April 11, 2020
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center studyLesley-Ann Sutton, Viktor Ljungström, Anna Enjuanes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic LeukemiaJeff P Sharman, Steven E Coutre, Richard R Furman, et al.Blood|October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W Flinn, Peter Hillmen, Marco Montillo, et al.Blood|September 30, 2022
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLLJohanna Stachelscheid, Qu Jiang, Christoph Aszyk, et al.The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.Hemasphere|June 17, 2026
IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.Pageof 40